Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16477959 | 0.95 | THRA (0.32) | PPARGPPARARAB9A | |
| SCHEMBL16477966 | 0.91 | PTPN11 (0.36) | MEN1KMT2APTPN11PDK2MAPT | |
| SCHEMBL17452488 | 0.91 | — | — | |
| SCHEMBL18012817 | 0.87 | PDK2 (0.36) | PPARGPPARARAB9AMEN1KMT2A | |
| SCHEMBL16477964 | 0.85 | — | — | |
| SCHEMBL16477961 | 0.84 | RAB9A (0.40) | RAB9APDK2MAPT | |
| SCHEMBL17056201 | 0.84 | PDK2 (0.41) | PPARGPPARAMEN1KMT2ACNR2 | |
| SCHEMBL16556664 | 0.82 | PDK2 (0.42) | PDK2 | |
| SCHEMBL17056226 | 0.81 | ALDH1A1 (0.34) | PPARGPPARARAB9AMEN1KMT2A | |
| SCHEMBL16477981 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382259-B2 | Compounds with oxime ester and/or acyl groups | AMERICAN DYE SOURCE, INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-9127017-B2 | Compounds with oxime ester and/or acyl groups | AMERICAN DYE SOURCE, INC. (CA) | 2015-09-08 | — | — | US | disclosed |
| US-20140200350-A1 | COMPOUNDS WITH OXIME ESTER AND/OR ACYL GROUPS | AMERICAN DYE SOURCE, INC. (CA) | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200350-A1 | COMPOUNDS WITH OXIME ESTER AND/OR ACYL GROUPS | PPOX, SCO2, LPO | PPARG 277/4885PPARA 304/4885RAB9A 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.